After a patient death in NKT trial, Athenex hires chief restructuring officer
Athenex is bringing on a chief restructuring officer as the Buffalo, NY-based biotech considers “strategic alternatives” following a clinical hold for its natural killer cell …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.